Risk of Next Melanoma in Patients With Familial and Sporadic Melanoma by Number of Previous Melanomas

Chen, Tianhui; Fallah, Mahdi; Försti, Asta; Kharazmi, Elham; Sundquist, Kristina; Hemminki, Kari

doi:10.1001/jamadermatol.2014.4777

Cited by 26 publications

(30 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The increasing number of patients diagnosed with invasive cutaneous malignant melanoma (CMM) that develop one or more additional CMMs, i.e., multiple primary invasive cutaneous malignant melanomas (MPMs), may be correlated to increasing incidence of CMM and improved survival over the last decades . The expected life time risk of an additional CMM varies between 1.3 and 8.6% . Several clinical and tumor‐related characteristics are associated with MPMs, e.g., older age, male gender, personal, or family history of CMM .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Reduced disease‐specific survival following a diagnosis of multiple primary cutaneous malignant melanomas—a nationwide, population‐based study

Utjés

Lyth

Lapins

et al. 2017

Intl Journal of Cancer

View full text Add to dashboard Cite

Outcome data comparing patients with multiple primary invasive cutaneous malignant melanomas (MPMs) to single primary invasive cutaneous malignant melanomas (SPMs) show conflicting results. We have analyzed differences in disease-specific survival between these patients in a nationwide population-based setting. From the Swedish Melanoma Register, 27,235 patients were identified with a first invasive cutaneous malignant melanoma (CMM) between 1990 and 2007, followed-up through 2013. Of these, 700 patients developed MPMs. Cox proportional hazard regression was used for adjusted cause-specific hazard ratios (HRs). An interval of ≤5 years between CMM diagnoses was significantly correlated to a decreased CMM-specific survival in Stage I-II MPM- vs. SPM-patients (HR 1.32; 95% CI 1.04-1.67; p = 0.02). MPM-patients with longer time interval between diagnoses experienced similar risk of CMM-death as SPM-patients. The risk of CMM-death increased by almost 50% above the expected outcome according to stage of the index CMM by the diagnosis of a second CMM (HR 1.48; 95% CI 1.19-1.85; p < 0.001). MPM vs. SPM-patients had a worse outcome (HR 1.38; 95% CI 1.05-1.83; p = 0.001). This emphasizes the importance of prevention efforts in SPM-patients to decrease the risk of subsequent CMMs and has implications for more vigilant follow-up in MPM-patients.

show abstract

mentioning

confidence: 99%

“…The expected life time risk of an additional CMM varies between 1.3 and 8.6% . Several clinical and tumor‐related characteristics are associated with MPMs, e.g., older age, male gender, personal, or family history of CMM . Decreasing tumor thickness in subsequent CMMs has been reported .…”

mentioning

confidence: 99%

Reduced disease‐specific survival following a diagnosis of multiple primary cutaneous malignant melanomas—a nationwide, population‐based study

Utjés

Lyth

Lapins

et al. 2017

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Thus, Sweden has a high proportion of patients diagnosed with a single primary melanoma at risk of developing multiple primary melanomas. There are a few previous studies investigating different aspects of multiple primary melanomas in Sweden, but none has focused on Western Sweden (12)(13)(14)(15). Over the past 20 years this geographical region has shown a higher incidence of melanoma than the national average, and is therefore an important area for melanoma research (16).…”

mentioning

confidence: 99%

Multiple Primary Melanomas: A Common Occurrence in Western Sweden

Claeson¹,

Holmström²,

Hallberg³

et al. 2017

Acta Derm Venerol

View full text Add to dashboard Cite

Patients diagnosed with a single primary cutaneous melanoma are at increased risk of developing multiple primary melanomas. The aim of this study is to describe the epidemiology of multiple primary melanomas (invasive and in situ) in Western Sweden. Data from the Swedish Melanoma Registry from 1990 to 2013 revealed that 898 patients (7.4%) developed 2,037 multiple primary lesions and 11,254 patients developed single lesions. The proportion of subsequent lesions that were melanoma in situ was 47%, compared with 26% of first melanomas (p < 0.0001).The median and mean time to diagnosis of a subsequent melanoma was 38 and 58 months (95% confidence interval (CI), 53-62 months). In total, 49% of subsequent melanomas were detected within 3 years. Patients and physicians should be aware of the high proportion of multiple primary melanomas in Western Sweden, especially during the first years of follow-up.

show abstract

“…Family history of melanoma should signal vigilance for clinical follow-up. 21,22 Our recent study showed that a family history of cancer X is a risk factor of second cancer X in melanoma patients. 7 Common SPCs with increased familial risks in melanoma patients included prostate, breast, colorectal and squamous cell skin cancers, for which screening methods would be available.…”

Section: Discussionmentioning

confidence: 99%

<p>Second Primary Cancers in Melanoma Patients Critically Shorten Survival</p>

Zheng¹,

Chattopadhyay²,

Sundquist³

et al. 2020

CLEP

Self Cite

View full text Add to dashboard Cite

Background: Survival in malignant cutaneous melanoma has improved but increasing survival will result in an increased likelihood of the occurrence of second primary cancers (SPCs). SPCs may adversely interfere with survival. We quantified survival in patients with different types of SPCs, in comparison to known poor prognostic indicators of metastatic disease. Methods: Data for melanoma and any SPCs were obtained from the Swedish Cancer Registry for years 2003 through 2015, including clinical TNM classification. SPCs were grouped into three 'prognostic groups' based on 5-year relative survival of these cancers as first primary cancer. Kaplan-Meier survival curves were generated and hazard ratios were estimated using Cox regression, adjusted for a number of variables and treating diagnosis of SPC as a time-dependent variable. Results: The total number of first melanoma patients was 28,716 followed by 3,202 (11.1%) SPCs, 1/3 of which had a second melanoma while 2/3 had other SPCs. Among men diagnosed at age over 70 years, who survived at least 10 years, 31.4% had SPC. HRs (95% CI) for survival increased systematically from the reference rate of 1.00 (no SPC) to 1.59 (1.35-1.87) with SPC of good prognosis (78.6% of SPCs) to 3.49 (2.58-4.72) of moderate prognosis (12.0%) and to 7.93 (5.50-11.44) of poor prognosis (9.4%). In patients without SPC, the HRs increased to 2.62 (2.02-3.39) with any nodal metastases and to 5.88 (4.57-7.57) with any distant metastases compared to patients without local or distant metastases. Conclusion: The data showed that SPCs are an increasingly common negative prognostic factor for melanoma. Future attempts to improve melanoma survival need to target SPCs.

show abstract

Risk of Next Melanoma in Patients With Familial and Sporadic Melanoma by Number of Previous Melanomas

Cited by 26 publications

References 24 publications

Reduced disease‐specific survival following a diagnosis of multiple primary cutaneous malignant melanomas—a nationwide, population‐based study

Reduced disease‐specific survival following a diagnosis of multiple primary cutaneous malignant melanomas—a nationwide, population‐based study

Multiple Primary Melanomas: A Common Occurrence in Western Sweden

<p>Second Primary Cancers in Melanoma Patients Critically Shorten Survival</p>

Contact Info

Product

Resources

About